Objective:
To evaluate the efficacy of off-label topical insulin eye drops for treating refractory dry eye disease (DED) and its impact on corneal staining and symptoms.
Key Findings:
- 38% of subjects reported feeling better after 3 months of treatment, indicating potential clinical relevance.
- Statistically significant improvements in both conjunctival hyperemia and corneal staining were observed, suggesting efficacy.
- Topical insulin was well tolerated by the subjects, with no reported adverse effects.
Interpretation:
Topical insulin may be a promising off-label treatment for patients with refractory dry eye disease, showing improvements in ocular health and symptom relief.
Limitations:
- Small sample size of 16 subjects limits generalizability.
- Retrospective design may introduce bias and confounding factors.
- Lack of a control group limits the ability to draw definitive conclusions.
Conclusion:
Off-label use of topical insulin for dry eye disease shows potential benefits, warranting further research with larger sample sizes to confirm efficacy and safety.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.